| Jeremy D Gray, DPM | |
|
12401 Hoffman Rd, Edmond, OK 73013-7550 | |
| (405) 919-5663 | |
| (405) 478-4423 |
| Full Name | Jeremy D Gray |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 17 Years |
| Location | 12401 Hoffman Rd, Edmond, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427206077 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 1951 (Texas) | Primary |
| Provider Name | David Quyen Le |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1962566307 PECOS PAC ID: 3678553781 Enrollment ID: I20040727001391 |
News Archive
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1
A study evaluating the effect of AHCC (Active Hexose Correlated Compound) on supporting the immune system in response to the swine flu virus will be conducted at the Southern China Agricultural University, one of the few research centers in China that have been approved to conduct studies on highly infectious diseases such as the swine flu. This controlled study will examine the effects of AHCC when supplemented to a group of mice infected with the virus.
As surgical teams gain experience with facial transplantation, a careful approach to planning based on the principles of craniofacial surgery can help to maximize patient outcomes in terms of facial form and function, according to an article in The Journal of Craniofacial Surgery.
An important new study shows that better T cell detection is now possible using revolutionary technology. T cells are a type of lymphocyte, which in turn belongs to the diverse family of immune cells. They take part in cancer fighting as well as in most other immune responses.
› Verified 5 days ago
| Provider Name | Gray's Foot & Ankle Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1851727770 PECOS PAC ID: 5496979056 Enrollment ID: O20140623000160 |
News Archive
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1
A study evaluating the effect of AHCC (Active Hexose Correlated Compound) on supporting the immune system in response to the swine flu virus will be conducted at the Southern China Agricultural University, one of the few research centers in China that have been approved to conduct studies on highly infectious diseases such as the swine flu. This controlled study will examine the effects of AHCC when supplemented to a group of mice infected with the virus.
As surgical teams gain experience with facial transplantation, a careful approach to planning based on the principles of craniofacial surgery can help to maximize patient outcomes in terms of facial form and function, according to an article in The Journal of Craniofacial Surgery.
An important new study shows that better T cell detection is now possible using revolutionary technology. T cells are a type of lymphocyte, which in turn belongs to the diverse family of immune cells. They take part in cancer fighting as well as in most other immune responses.
› Verified 5 days ago
| Provider Name | Diabetic Foot And Wound Center Of Okfas |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1780171009 PECOS PAC ID: 4981959509 Enrollment ID: O20180621001511 |
News Archive
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1
A study evaluating the effect of AHCC (Active Hexose Correlated Compound) on supporting the immune system in response to the swine flu virus will be conducted at the Southern China Agricultural University, one of the few research centers in China that have been approved to conduct studies on highly infectious diseases such as the swine flu. This controlled study will examine the effects of AHCC when supplemented to a group of mice infected with the virus.
As surgical teams gain experience with facial transplantation, a careful approach to planning based on the principles of craniofacial surgery can help to maximize patient outcomes in terms of facial form and function, according to an article in The Journal of Craniofacial Surgery.
An important new study shows that better T cell detection is now possible using revolutionary technology. T cells are a type of lymphocyte, which in turn belongs to the diverse family of immune cells. They take part in cancer fighting as well as in most other immune responses.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeremy D Gray, DPM 12401 Hoffman Rd, Edmond, OK 73013-7550 Ph: (405) 919-5663 | Jeremy D Gray, DPM 12401 Hoffman Rd, Edmond, OK 73013-7550 Ph: (405) 919-5663 |
News Archive
Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of refractory advanced colorectal cancer.
New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1
A study evaluating the effect of AHCC (Active Hexose Correlated Compound) on supporting the immune system in response to the swine flu virus will be conducted at the Southern China Agricultural University, one of the few research centers in China that have been approved to conduct studies on highly infectious diseases such as the swine flu. This controlled study will examine the effects of AHCC when supplemented to a group of mice infected with the virus.
As surgical teams gain experience with facial transplantation, a careful approach to planning based on the principles of craniofacial surgery can help to maximize patient outcomes in terms of facial form and function, according to an article in The Journal of Craniofacial Surgery.
An important new study shows that better T cell detection is now possible using revolutionary technology. T cells are a type of lymphocyte, which in turn belongs to the diverse family of immune cells. They take part in cancer fighting as well as in most other immune responses.
› Verified 5 days ago
Steven Walker, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 600 W 15th St, Edmond, OK 73013 Phone: 405-340-9251 Fax: 405-340-0686 | |
Armando Carro, Jr Dpm, Inc Podiatrist Medicare: Medicare Enrolled Practice Location: 600 W 15th St, Edmond, OK 73013 Phone: 405-348-4141 | |
Dr. Barbara Jean Barrett, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 400 N Bryant Ave, Edmond, OK 73034 Phone: 405-230-9200 Fax: 405-230-9245 | |
Central Oklahoma Foot & Ankle Centers Pllc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1404 E 9th St, Edmond, OK 73034 Phone: 405-285-8538 | |
Armando Carro, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 600 W 15th St, Edmond, OK 73013 Phone: 405-340-9251 Fax: 405-340-0686 | |
Gordon J Bean Dpm Inc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 600 W 15th St, Edmond, OK 73013 Phone: 405-340-9251 Fax: 405-340-0686 |